JPWO2021256555A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021256555A5 JPWO2021256555A5 JP2022531930A JP2022531930A JPWO2021256555A5 JP WO2021256555 A5 JPWO2021256555 A5 JP WO2021256555A5 JP 2022531930 A JP2022531930 A JP 2022531930A JP 2022531930 A JP2022531930 A JP 2022531930A JP WO2021256555 A5 JPWO2021256555 A5 JP WO2021256555A5
- Authority
- JP
- Japan
- Prior art keywords
- binding molecule
- pharmaceutical composition
- cell antigen
- subject
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000027455 binding Effects 0.000 claims 35
- 239000000427 antigen Substances 0.000 claims 25
- 102000036639 antigens Human genes 0.000 claims 25
- 108091007433 antigens Proteins 0.000 claims 25
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 239000003246 corticosteroid Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- 102000010956 Glypican Human genes 0.000 claims 4
- 108050001154 Glypican Proteins 0.000 claims 4
- 108050007237 Glypican-3 Proteins 0.000 claims 4
- 206010052015 cytokine release syndrome Diseases 0.000 claims 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 2
- 102100032530 Glypican-3 Human genes 0.000 claims 2
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims 2
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 2
- 102000009490 IgG Receptors Human genes 0.000 claims 2
- 108010073807 IgG Receptors Proteins 0.000 claims 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 2
- 229960002833 aflibercept Drugs 0.000 claims 2
- 108010081667 aflibercept Proteins 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- 230000008472 epithelial growth Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960002633 ramucirumab Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023043678A JP2023078311A (ja) | 2020-06-19 | 2023-03-20 | 血管新生阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020106501 | 2020-06-19 | ||
| JP2020106501 | 2020-06-19 | ||
| PCT/JP2021/023149 WO2021256555A1 (ja) | 2020-06-19 | 2021-06-18 | 血管新生阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023043678A Division JP2023078311A (ja) | 2020-06-19 | 2023-03-20 | 血管新生阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021256555A1 JPWO2021256555A1 (https=) | 2021-12-23 |
| JPWO2021256555A5 true JPWO2021256555A5 (https=) | 2022-11-25 |
| JP7250219B2 JP7250219B2 (ja) | 2023-03-31 |
Family
ID=79268097
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022531930A Active JP7250219B2 (ja) | 2020-06-19 | 2021-06-18 | 血管新生阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子 |
| JP2023043678A Withdrawn JP2023078311A (ja) | 2020-06-19 | 2023-03-20 | 血管新生阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023043678A Withdrawn JP2023078311A (ja) | 2020-06-19 | 2023-03-20 | 血管新生阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230235056A1 (https=) |
| EP (1) | EP4186527A4 (https=) |
| JP (2) | JP7250219B2 (https=) |
| KR (2) | KR102594943B1 (https=) |
| CN (1) | CN115768478A (https=) |
| AU (1) | AU2021292932A1 (https=) |
| BR (1) | BR112022025536A2 (https=) |
| CA (1) | CA3180951A1 (https=) |
| CL (1) | CL2022003622A1 (https=) |
| CR (1) | CR20230014A (https=) |
| IL (1) | IL299127A (https=) |
| MX (1) | MX2022015764A (https=) |
| PE (1) | PE20230435A1 (https=) |
| TW (1) | TW202214286A (https=) |
| WO (1) | WO2021256555A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3434767T (pt) | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| WO2025120867A1 (en) * | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| TW202539742A (zh) * | 2024-02-08 | 2025-10-16 | 大陸商上海翰森生物醫藥科技有限公司 | 抗體藥物偶聯物和抗ｖｅｇｆ抗體的聯合應用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773719A (en) | 1966-12-06 | 1973-11-20 | Hoffmann La Roche | 2-aminoxy-2'-acyl-acetanilide |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| EP2144931A2 (en) | 2007-04-04 | 2010-01-20 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Monoclonal antibodies against dengue and other viruses with deletion in fc region |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| PT3434767T (pt) | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| AU2015244814B2 (en) | 2014-04-07 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| US11072666B2 (en) * | 2016-03-14 | 2021-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
| WO2018038046A1 (ja) | 2016-08-22 | 2018-03-01 | 中外製薬株式会社 | ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物 |
| JP7784795B2 (ja) * | 2016-11-15 | 2025-12-12 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与 |
| US20200101108A1 (en) * | 2017-03-31 | 2020-04-02 | The Board Of Trustees Of The Le-Land Standford Junior University | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
-
2021
- 2021-06-18 MX MX2022015764A patent/MX2022015764A/es unknown
- 2021-06-18 AU AU2021292932A patent/AU2021292932A1/en not_active Abandoned
- 2021-06-18 CA CA3180951A patent/CA3180951A1/en active Pending
- 2021-06-18 BR BR112022025536A patent/BR112022025536A2/pt unknown
- 2021-06-18 IL IL299127A patent/IL299127A/en unknown
- 2021-06-18 KR KR1020227039674A patent/KR102594943B1/ko active Active
- 2021-06-18 PE PE2022002932A patent/PE20230435A1/es unknown
- 2021-06-18 KR KR1020237036198A patent/KR20230152789A/ko active Pending
- 2021-06-18 WO PCT/JP2021/023149 patent/WO2021256555A1/ja not_active Ceased
- 2021-06-18 CN CN202180043015.4A patent/CN115768478A/zh active Pending
- 2021-06-18 US US18/010,615 patent/US20230235056A1/en active Pending
- 2021-06-18 JP JP2022531930A patent/JP7250219B2/ja active Active
- 2021-06-18 CR CR20230014A patent/CR20230014A/es unknown
- 2021-06-18 TW TW110122300A patent/TW202214286A/zh unknown
- 2021-06-18 EP EP21825999.2A patent/EP4186527A4/en not_active Withdrawn
-
2022
- 2022-12-16 CL CL2022003622A patent/CL2022003622A1/es unknown
-
2023
- 2023-03-20 JP JP2023043678A patent/JP2023078311A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | The state of the art of bispecific antibodies for treating human malignancies | |
| CA2945902C (en) | Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof | |
| JPWO2021256555A5 (https=) | ||
| US12398209B2 (en) | Methods of treating cancers with antagonistic anti-PD-1 antibodies | |
| JP2021168661A (ja) | 三重特異性結合タンパク質と使用方法 | |
| Kaiser | Emerging therapies for neovascular age-related macular degeneration: drugs in the pipeline | |
| TWI908743B (zh) | 抗dll3藥劑之給藥方案 | |
| JP2018012705A (ja) | 抗ｖｅｇｆ抗体での治療 | |
| US20230101029A1 (en) | Methods of using il-33 protein in treating cancers | |
| JPH08504172A (ja) | 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法 | |
| CN104684579A (zh) | 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用 | |
| JP2014532072A5 (https=) | ||
| JP2019514846A (ja) | 免疫チェックポイントモジュレーターとのｔ細胞リダイレクティング多機能抗体の組み合わせとその使用 | |
| CN102170908A (zh) | 向个体的肿瘤引流淋巴结递送cd40激动剂 | |
| CN103536917B (zh) | 干扰素在治疗肿瘤中的用途及相关的产品和方法 | |
| CN113271964A (zh) | 化脓性汗腺炎治疗中使用的抗cd40抗体 | |
| WO2019184282A1 (zh) | 特异结合人质膜膜泡关联蛋白pv-1的单克隆抗体及其制备方法与应用 | |
| CN105251004A (zh) | 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物 | |
| US20250340634A1 (en) | Dosage regimens for anti-cd19 agents and uses thereof | |
| Parrondo et al. | Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives | |
| Magarotto et al. | Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: a new era begins | |
| BR112020017445A2 (pt) | anticorpos anti cd6 para tratar asma severa | |
| Tacchetti et al. | Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma | |
| JP7539609B2 (ja) | 抗－ｃｄ３００ｃ単クローン抗体を含むがん予防または治療用組成物 | |
| WO2025190337A1 (zh) | 使用抗EpCAM×CD3双特异性抗体改善或治疗恶性腹水的方法 |